Project Grant R01CA291994
Award Date 9/23/25
Completion Date 7/31/30
Dollars Obligated $477K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Illinois, USA
Similar Awards
- The National Cancer Institute (NCI), under the Cancer Biology Research federal grant program (CFDA 93.396), awarded a $530,106 Project Grant to the Children's Hospital Medical Center in Cincinnati, Ohio. The grant, awarded on September 11, 2025, supports research aimed at understanding and targeting polyamine metabolism in leukemia stem cells (LSCs) to improve outcomes for patients with acute myeloid leukemia (AML). The overarching goal is to develop LSC-directed therapies that can help overcome...
- This Project Grant award of $662,938, provided by the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), supports research at Northwestern University to investigate the role of gain-of-function mutant p53 proteins in acute myeloid leukemia (AML). The central objective is to determine how these p53 mutations promote leukemia-initiating cell self-renewal, chromatin accessibility, and 3D chromatin structure, which may contribute to therapy resistance in AML....
- The National Cancer Institute (CFDA 93.396 - Cancer Biology Research) awarded a $1,625,853 Project Grant to New York University (NYU) on December 13, 2024. The grant will support NYU's research to map and characterize the role of 3D "hubs" - regulatory DNA elements that interact with multiple loci - in the context of T-cell leukemia (T-ALL), early T-cell progenitor leukemia (ETP-ALL), and T-cell lymphoma. The project aims to better define how these 3D chromatin structures are rewired...
- This federal Project Grant award of $344,111.00 was provided by the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) to Loyola University of Chicago's Health Sciences Campus division. The grant supports research aimed at understanding the fundamental biological mechanisms of myelodysplastic syndromes (MDS), a group of bone marrow failure diseases that can transform into acute myeloid leukemia. The research focuses on targeting "panoptotic pathways" -...
- The National Cancer Institute awarded a $167,500 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to The Feinstein Institutes For Medical Research in New York. The grant supports research to understand the communication between cancer cells and cancer-associated fibroblasts in chronic lymphocytic leukemia (CLL). The project aims to identify potential therapeutic targets within the CLL tumor microenvironment in order to improve treatment outcomes. Specifically, the research...
- This $458,698 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research at the University of Michigan to identify cellular and molecular mechanisms underlying therapy resistance and disease relapse in acute myeloid leukemia (AML). The project aims to characterize genes and pathways that confer growth advantages to leukemic stem cells, enabling them to persist and regenerate disease after initial clinical remission. This 5-year...
- This $726,828 Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) to Northwestern University supports comprehensive research to investigate the role of adverse social-biological interactions in acute myeloid leukemia (AML) disparities. The key objectives are to: 1) develop a neighborhood stress scale and link it to adverse genomic characteristics of AML and clinical outcomes; 2) conduct a prospective study on the effects of self-reported...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides funding to Case Western Reserve University to conduct research aimed at understanding the fundamental biological mechanisms of acute myeloid leukemia (AML) and developing new therapeutic approaches. The $491,357 award supports investigations into using proteasome inhibitors and an mTORC1 activator molecule to induce metabolic stress and resensitize AML cells to treatment, particularly...
- The National Cancer Institute (NCI) awarded a $1,034,176 Project Grant to the Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) with an award date of August 18, 2025. The grant aims to understand the mechanisms of aberrant RNA splicing and how it drives the development of various hematological malignancies, including myelodysplastic syndrome, chronic lymphocytic leukemia, and acute myeloid leukemia. The research builds on the institution's past...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $439,644 to The Leland Stanford Junior University to conduct functional studies on human acute myeloid leukemia (AML) stem cells. The key objectives are to: 1) Investigate the relationship between specific genetic mutations and AML stem cell frequency, disease initiation, and disease maintenance by correcting mutations in primary AML cells and AML-induced pluripotent stem cells (iPSCs);...